|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.0400 - 1.1100|
|52 Week Range||0.8500 - 2.0400|
|Beta (3Y Monthly)||3.04|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Supreme Cannabis Company Inc (OTC: SPRWF ) announced that the Supreme Court of British Columbia has released a final order approving previously announced agreement to acquire Blissco Cannabis Corp. (OTC: ...
Of the multiple positive catalysts should fuel Aphria Inc (NYSE:APHA) in the months ahead, the most intriguing one is is vaping, or using a vaporizer to get the desired effect from cannabis use. My InvestorPlace colleague Will Healy pointed out some of these catalysts in his June 6 article, when APHA stock was trading at more than 50% below its 52-week high.Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe next day, Aphria announced that it had entered into a supply agreement for the Canadian market with San Francisco-based Pax Labs, a leader in the manufacture and sale of vaporizers. In the U.S. alone, Pax has sold more than 500,000 Era vaporizers to date with plenty of growth expected in the months and years ahead. "As Aphria continues to drive the evolution of the industry, we are thrilled to partner with a technology leader like PAX to provide a new avenue for consumers to integrate cannabis into their lives," said Irwin Simon, interim CEO of Aphria. "We are excited to bring our premium cannabis extracts from Solei, RIFF and our flagship medical cannabis brand, Aphria, to the PAX Era device and platform." Vaping is Going to Be Big in CanadaThe vaping market in Canada is expected to be significant. Aphria estimates that vapes and concentrates will account for up to 30% of the entire adult-use market by 2021. The great thing about vaping, from Aphria's perspective, is that concentrates provide a much higher margin than dried cannabis. * 7 Stocks to Buy for a Dovish Fed Statistics show that U.S. use of vape products is growing, while the use of dried flower is slowing. In Colorado, the use of vape products increased tremendously over three years. In 2014, vape products accounted for 12% of the legal market. By 2017, that number had grown to 23%. Meanwhile, over the same three years, the use of dried flower dropped by 12 percentage points to 54% of the market. Between edibles, concentrates, and infused drinks, the cannabis industry is moving away from the dried flower to an industry filled with choice. The fact that Aphria is partnering with one of the premier vape companies is a sign that Simon understands the importance of moving beyond supplying dried buds. APHA Is Not AloneThat only downside from Aphria's announcement is that PAX pick three other Canadian cannabis producers to help sell its product: Aurora Cannabis (NYSE:ACB), OrganiGram (NASDAQ:OGI), and Supreme Cannabis (OTCMKTS:SPRWF). However, the fact that Aphria is near completion of it $55 million Extraction Centre of Excellence in Leamington, Ontario, makes this concern far less of an issue. That's because when completed, Aphria will have annual extraction capacity of 200,240 kilograms, making it one of the largest extractors in Canada. Currently, analysts haven't factored Aphria's extraction facility into their valuation models. Once the facility is running, and products are available for sale in late December or early in 2020, Aphria stock is going to be far more attractive to investors than it is today. Bottom Line on Aphria StockIn May, I highlighted the pros and cons of the regime change at Aphria. As I stated, it's hard to know if Irwin Simon's the right person for the job. While his work at Hain Celestial (NASDAQ:HAIN) was at times exceptional, in recent years he did little to impress investors, eventually stepping down as CEO in June 2018. * The Top 8 Tech Stocks of 2019 (So Far) Joining the Aphria Inc board in December as chairman, Simon was appointed interim CEO on March 1 after former boss Vic Neufeld retired in January. Since then, Simon's made a few management changes to put his own stamp on the company. The PAX announcement is a sign Simon might be sticking around as the permanent CEO. If the board didn't have confidence in him, this kind of deal probably wouldn't have happened. While not completely sold on Simon, the PAX deal in combination with the completion of the extraction plant, suggests investors aren't giving Aphria stock its due.Aggressive investors ought to consider buying this potential growth and value play. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Top Small-Cap Stocks Of 2019 * Critical Levels to Watch in 7 Marijuana Stocks * 5 Smaller Cloud Stocks That Have Plenty of Potential Compare Brokers The post Can Vaping Growth Help Investors Extract More Value From Aphria Stock? appeared first on InvestorPlace.
Supreme Cannabis Company Inc (OTC: SPRWF) on Tuesday launched a premium cannabis oil in partnership with Khalifa Kush Enterprises Canada. The KKE Oil is the first product under the KKA brand line developed under the partnership between Supreme Cannabis Company and rapper Wiz Khalifa's Khalifa Kush Enterprises Canada. It uses Sensi Star strain developed by 7ACRES, a wholly-owned subsidiary of Supreme Cannabis.
[Editor's Note: This story was previously published in February 2019. It has since been updated and republished.]The 2018 midterm elections made clear that Americans preferred legalization over the continued prohibition of pot, which should bolster the case for the top marijuana penny stocks.When residents in California voted for full recreational weed, it boded well not just for marijuana penny stocks, but for electoral momentum in other states and the midterms emphatically proved this point.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn conservative Utah and Missouri, voters approved medical cannabis. But Michigan stood above the rest, becoming the tenth state to legalize recreational marijuana. Significantly, it's also the first Midwestern state to approve such an initiative.Previously embattled marijuana stocks like Cronos Group (NASDAQ:CRON), Aurora Cannabis (NYSE:ACB) and Canopy Growth (NYSE:CGC) received a much-needed boost in the markets and really have capitalized on it.It's not difficult to understand why many investors believe in weed. Not only does legal marijuana open doors to a previously inaccessible sector, it has proven economic benefits. The commonly cited case study is Colorado. In 2015, one year after green lighting cannabis businesses, the botanical industry nearly hit $1 billion in revenue. In 2016, it breached the threshold, and growth remains strong. Considering that so many states suffer from budget shortfalls, a little green could go a long way.Plus, the sharp war of words and tariffs in U.S.-China trade relations amps up the case for marijuana penny stocks. Multiple industries, especially agriculture, are hurting. Full legalization provides an easy catalyst for economic activity and growth. * 7 High-Quality Cheap Stocks to Buy With $10 Under this backdrop, gambling on top marijuana penny stocks is more compelling than jumping on any other speculative venture. While risks abound, these four sector players offer considerable upside possibilities. Auxly Cannabis Group (CBWTF)A common difficulty in forecasting future price movements for top marijuana penny stocks is separating hype from reality. While almost every sector player advertises significant upside potential, most undercapitalized firms fail to deliver the goods.I had high hopes for Auxly Cannabis (OTCMKTS:CBWTF) last year due to its unique business structure. Auxly earned bragging rights for becoming the first cannabis streaming company.Energy and mining companies typically deploy the streaming model to gain full access to an industry's supply chain without incurring unnecessary risk. In theory, streaming is the way to go for marijuana-related organizations. Even with Canada's legalization initiative and U.S. electoral momentum, several legal and administrative hurdles exist. Streaming facilitates exposure to a lucrative industry, but with "stop gaps" should things go awry.Unfortunately, the markets have not been kind to Auxly stock. Since its January opener, shares have lost more than half their equity value.Nevertheless, I'm still hopeful that Auxly can pull it together. One of the major challenges for the company is that its streaming partners still encounter arguably unreasonable non-cannabis related obstacles. The biggest on the list is securing traditional financing, which stymies expansion efforts.However, the cannabis industry is making steady steps toward mainstream institutional acceptance. And especially with the U.S.-China trade war heating up, even conservative administrations can't afford overlooking a key revenue-maker. MPX Bioceutical (MPXEF)A common stereotype about legal-cannabis advocates is that they have ulterior motives for their product evangelism. Although that could be the case, one thing is undeniable: many, if not most top marijuana penny stocks focus on botany's medicinal aspect.This is especially true for MPX International (OTCMKTS:MPXOF). MPX operates three brands under its corporate umbrella: Salus BioPharma, Health for Life and its namesake MPX.The former two divisions specialize in medical-grade cannabis, while the latter caters to the green lifestyle. Salus is particularly intriguing as it represents a joint venture with Israeli pharmaceutical Panaxia to develop proprietary, smokeless cannabis products.Another compelling driver for MPXOF stock is its recent partnership with South Africa's First Growth Holdings. Primarily, this is an attractive deal because South Africa provides ample land and inexpensive labor. Moreover, the country recently legalized weed, so it provides MPX with global revenue synergies. Granted, management must make investments to ensure the higher-quality inventory which western connoisseurs desire. Nevertheless, the cost outlay should be very reasonable compared to other locales. * 7 Top-Rated Biotech Stocks to Invest In Today That's not to say you should jump on MPXOF stock without worries. The company isn't what you would consider fundamentally sound. Still, with relatively stable market performance and an impressive growth rate, speculators will want to keep close tabs on MPX. Supreme Cannabis Company (SPRWF)When Canada became the first G7 nation to approve recreational weed in October 2018, it actually forged the path forward for marijuana startups. As a result, the lion's share of marijuana penny stocks is based in Canada.A prime example is Supreme Cannabis Company (OTCMKTS:SPRWF). Supreme Cannabis, whose 7ACRES brand of medical-grade cannabis started life as a father seeking alternative therapies for his daughter.Eventually, 7ACRES grew to become a gold-standard cannabis facility, offering distinct, high-quality strains.What makes SPRWF stand out compared to other top marijuana penny stocks is that management is focused on a business-to-business (B2B) strategy. This enables the company to fine-tune its craft, rather than dilute its effectiveness through disparate supply-chain segments.Over the long run, I think this higher-end focus will distinguish SPRWF stock from the competition. For example, several mainstream retail stores, including Neiman Marcus and Vitamin Shoppe (NYSE:VSI), have pushed for cannabidiol, or CBD, products.Obviously, that's a big plus for the broader marijuana industry. But just selling bottom-shelf weed at large volume isn't going to cut it. Consumers want differentiation, which is what Supreme Cannabis offers. Therefore, SPRWF stock has a chance to positively surprise.That said, this is a very volatile market. SPRWF stock is a high-risk, high-reward venture, but a very tempting one due to positive industry-related developments. Cannabis Science (CBIS)Cannabis Science (OTCMKTS:CBIS) is easily one of the most speculative among top marijuana penny stocks. Immediately, you can tell that through either its ridiculously low share price, or its sub-$100 million market capitalization.Another giveaway is Cannabis Science's bold declaration to provide innovative therapies for unmet medical needs, including cancer. As the old saying goes, extraordinary claims require extraordinary evidence.But this is also where CBIS stock becomes interesting. Management claims that cannabis use dates back thousands of years, making it one of the most tried-and-true medicines. Plus, traditional pharmaceutical companies have become more a marketing machine than a therapy provider. Therefore, the medical-cannabis industry deserves at least some credibility.Also, I think it's fair to point out that the opioid crisis has caused mainstream pharmaceuticals to lose credibility. Despite best intentions, the pharmaceutical industry has left a wave of problems in its wake. This could negatively impact generations of Americans. Thus, marijuana penny stocks related to medical cannabis could benefit.That's the good news for CBIS stock. The not so great news is that shares continue to struggle. * 7 U.S. Stocks to Buy With Limited Trade War Exposure Conservative investors should probably stay away from Cannabis Science and marijuana penny stocks in general. But if you're a speculator, CBIS stock appears to have bottomed after a recent bout of volatility. It's no guarantee of upside, but it might be worth a shot with gambling money.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 5 Red-Hot IPO Stocks to Buy for the Long Run * 5 Stocks to Buy for $20 or Less * 4 Dow Jones Stocks Ready to Rise Compare Brokers The post 4 Top Marijuana Penny Stocks to Take Seriously in 2019 appeared first on InvestorPlace.
Aurora Cannabis Inc. shares were in focus again Thursday, as investors continued to digest weaker-than-expected earnings and the company’s plans to grow its business.
Under the terms of the agreement, shareholders of Blissco will be offered 0.24 shares of Supreme Cannabis Company for each share they hold. Blissco, which positions itself as a premium wellness cannabis brand, will join Supreme Cannabis’ portfolio of brands and will operate as Supreme’s health and wellness business. The acquisition will give Supreme Cannabis Company access to Blissco’s 18,000 square foot production facility in Langley, British Columbia.
The Supreme Cannabis Co. Inc. said Thursday it has reached an agreement to acquire Blissco Cannabis Corp. in an all-stock deal valued at about C$48 million ($36 million). Under the terms of the deal, Blissco shareholders will receive 0.24 of Supreme Cannabis common stock. Blissco is a wellness brand that makes cannabis oils based in Langley, British Columbia, that operates a 18,000 square foot production facility with extraction capabilities. Blissco Chief Executive Damian Kettlewell will continue to lead the company and has committed to stay with Supreme Cannabis with at least 75% of his shares for a minimum of two years. The deal must be approved by shareholders at a special meeting. Neither stock was active premarket. Supreme Cannabis shares have gained 46% in 2019 to date, while the S&P 500 has gained 4.7%.
Cannabis Sector Extended Its Losses Last Week(Continued from Prior Part)Cannabis stocks fellLast week, most of the stocks in the cannabis sector ended lower. The Horizons Marijuana Life Sciences ETF (HMMJ) fell ~1.2%, while the ETFMG Alternative
ACB Trades Sideways ahead of Its Earnings Results(Continued from Prior Part)Sector performanceThe cannabis sector has been trading broadly flat ahead of the first-quarter earnings season. The Horizons Marijuana Life Sciences ETF (HMMJ) was up
Investors and major cannabis execs were in the same room April 17-18 at Benzinga's Cannabis Capital Conference in Toronto. Cannabis has the "power to transform human and wellness," said Robert Fireman, president and CEO of Marimed Inc (OTC: MRMD). One of the ways the medical cannabis company makes its mark is by offering a pure CBD product to treat children suffering from epilepsy, he said.
Cannabis Sector: Analyzing the Biggest Gains Last WeekWeekly gainersThe week ending April 26 brought some relief to cannabis sector investors. The Horizons Marijuana Life Sciences ETF (HMMJ) rose as much as 5.2%, while the ETFMG Alternative Harvest
Hexo (NYSE: HEXO) and Supreme Cannabis (OTC: SPRWF) are two options that still have significant upside for investors, which isn't easy to say for many cannabis stocks.Source: Shutterstock It's been a good year for cannabis stocks. But with several of the largest, most popular cannabis stocks already up more than 70% year-to-date, the marijuana space is looking fairly expensive. Given the lofty valuations in the cannabis group, some investors are looking for under-the-radar ways to play the marijuana trend.Bank of America recently initiated coverage of cannabis stocks. Their picks included popular cannabis plays Canopy Growth Corp. (NYSE: CGC) and Aurora Cannabis (NYSE: ACB). But Hexo and Supreme are couple of top picks that aren't typically among the most popular pot stocks.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Dividend Stocks That Could Double Over the Next Five Years Cannabis Stocks To Buy: HEXOSurprisingly, Bank of America analyst Christopher Carey named HEXO stock his top cannabis pick. Hexo is a cannabis company based in Quebec that has national distribution in Canada. It is also the preferred supplier of the province of Quebec.Aurora and Canopy are the two big dogs in Canadian production. Canopy's $16.2 billion market cap and Aurora's $9.1 billion market cap reflect those positions. However, Hexo is aggressively pushing to move into the top five.Hexo recently announced a buyout of Canada's Newstrike Brands for $263 million, the largest merger between two Canadian cannabis producers in history. The merger will quadruple Hexo's cultivation space from 579,000 square feet to more than 2.3 million square feet.Given HEXO stock is already up more than 100% year-to-date, its far from cheap compared to a few months ago. However, for investors looking for a long-term play on the cannabis trend, Hexo's $1.4 billion market cap leaves plenty of room for expansion.Carey says Quebec is home to 25% of Canada's legal-aged residents. He also says the company's five-year contract with Quebec de-risks the HEXO stock outlook, making it the safest Canadian cannabis stock."It is compelling on valuation vs peers… and with fundamentals grounded by the most de-risked cannabis supply in Canada (off-take with Quebec), an innovation-forward organization and potential for additional value-add partnerships," Carey says.Even after HEXO stock doubled in early 2019, Carey has a C$14 price target for HEXO. That target suggests an nearly 50% additional upside from current levels. Cannabis Stocks To Buy: Supreme CannabisHexo caught many stock investors off guard as Bank of America's top pick. However, investors looking for a true under-the-radar pick should consider Supreme Cannabis. Supreme is based in Ontario. It is focused primarily on the premium end of the cannabis market. As of 2019, the company operates mostly in the Canadian market. In the longer-term, it has plans to expand its business globally.Supreme is not in the same league as the other cannabis stocks I mentioned in terms of the size of its operation. SPRWF stock has a market cap of under $500 million. In March, Supreme announced a 50% increase in its total 7ACRES production space, which is still only 180,000 square feet. The company said it plans to hit 50,000 kg of annual production capacity by mid-2019.SPRWF stock is up 55% in 2019, but it has lagged its larger, high-flying peers. Carey says Supreme is selling in bulk to Canadian peers at around the same price peers are selling their product at retail. That's a testament to the pricing power of Supreme's product. Carey says Supreme's wholesale business gives the company flexibility over the next couple of years while it builds its retail processing and packaging operations.The potential downside to the wholesale business is that Supreme may be missing out on opportunity to build its brand among retail buyers. Supreme's 7ACRES was named "Brand of the Year" at the 2018 Canadian Cannabis Awards. But if the majority of the product is being sold to peers rather than consumers, Supreme may be missing out on a brand-building opportunity in the fledgling Canadian market.For cannabis stock investors looking for a high-risk/high-reward play, SPRWF stock may be the best opportunity out there. Safest Way To Play Cannabis StocksIt's always exciting to find under-the-radar stocks to buy and feel like you have a unique play on an idea like cannabis investing. However, the safest and smartest bets are typically the ones that minimize risk and maximize diversification.Investors like Warren Buffett who have been consistently successful over time tend to focus on companies that are best-of-breed and have leading market shares. In cannabis, those companies are Canopy and Aurora.But an even safer approach to cannabis stocks is buying an ETF. The recently-launched AdvisorShares Pure Cannabis ETF (NYSE: YOLO) launched just this month and holds around 40 different stocks. No matter which companies emerge as the winners, the YOLO ETF should benefit.As of this writing, Wayne Duggan did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks That Could Double Over the Next Five Years * 6 S&P 500 Stocks Ready to Break Out * 5 Mining ETFs to Dig Into Compare Brokers The post 2 Under-The-Radar Cannabis Stocks with Significant Growth Potential appeared first on InvestorPlace.
Cannabis Stocks Keep Falling(Continued from Prior Part)HEXO gainsHEXO (HEXO) has been one of the best performers so far this year in the cannabis sector. The stock has returned almost 10.1% in April alone, and it has returned more than an enviable
Speaking Wednesday to the Benzinga Cannabis Capital Conference in Toronto, 420 Investor author Alan Brochstein moderated a panel of representatives from some of the leading cannabis suppliers serving the Canadian market discussing how their companies have so far approached finding a share of the still-nascent industry. One of the major choke points affecting the Canadian market is meeting demand. Scott Walters, VP of corporate development with The Supreme Cannabis Co. Inc. (OTC: SPRWF), characterized the shift after the Oct. 17 legalization.
Biggest Gainers in the Cannabis Sector Last Week(Continued from Prior Part)Tilray fell last week Last week, Tilray (TLRY) emerged as the biggest loss. The stock lost nearly 9% of the value from the closing on March 29 to the closing on April 5. The
CannTrust Fell Last Week after Its Earnings AnnouncementCannabis sector last weekIn the week ending March 29, the cannabis sector fell. Concerns about a recession hitting the market outweighed investors’ sentiment. The Horizons Marijuana Life
How Cannabis Stocks' Valuations Stack Up amid Recent Weakness(Continued from Prior Part)Comparable multiples The cannabis sector’s median forward EV-to-EBITDA (enterprise value-to-earnings before interest, tax, depreciation, and amortization)
How Cannabis Stocks' Valuations Stack Up amid Recent Weakness(Continued from Prior Part)Comparing valuation multiplesAs of March 22, the median forward EV-to-sales multiple of our select group of 12 cannabis players was 7.0x. There were a couple of
March Update: Analysts’ Ratings for TLRY, IIPR, and SPRWF(Continued from Prior Part)Supreme Cannabis Supreme Cannabis (SPRWF), unlike its peers (HMMJ) including CannTrust (CTST), HEXO (HEXO), and Cronos Group (CRON), hasn’t received much
GMP Securities Upgrades Aurora Cannabis to a 'Buy'Aurora Cannabis upgradedGMP Securities, which previously had a “hold” rating on Aurora Cannabis (ACB), upgraded the company to a “buy” on March 13. The company also gave ACB a price target of
TLRY Is Too Rich for Jefferies—What about Other Cannabis Players?(Continued from Prior Part)Cannabis sector multiplesNow, let’s look at another valuation multiple for the same 12 cannabis players: the forward EV-to-EBITDA (enterprise
Analysts' Ratings Change for APHA, ACB, and CRON in March(Continued from Prior Part)Aurora Cannabis Aurora Cannabis (ACB) came under renewed attention. On March 5, Cowen initiated coverage on Aurora Cannabis (ACB) with an “outperform” rating. The
Key for Investors: Watching Cannabis Sector Valuations(Continued from Prior Part)Five other stocksIn this part, we’ll discuss the forward EV-to-EBITDA multiple for the other five cannabis stocks that we didn’t discuss in the previous part.
Key for Investors: Watching Cannabis Sector Valuations(Continued from Prior Part)What investors are payingBy knowing what investors are paying for each unit of the forward sales estimate for Cronos Group (CRON), HEXO (HEXO), and other companies,
Just as investors who follow the stock market have heard of Apple (NASDAQ:AAPL), Amazon (NASDAQ:AMZN), and Microsoft (NASDAQ:MSFT), investors who follow the cannabis industry have heard of that industry's giants of marijuana stocks, like Canopy Growth (NYSE:CGC), Aurora Cannabis (NYSE:ACB), and Tilray (NASDAQ:TLRY).And just like there are strong opportunities aside from the largest tech names, there are also a handful of cannabis stocks that trade at much better valuations than the names saturating the media.My goal is to find those stocks before they are household names -- the ones still flying under the radar that have huge upside potential.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis type of stock is not widely following on Wall Street. It's not the topic of conversation at the water cooler. But that's actually a good thing …It is precisely these unknown stocks that have upside potential that often far outweighs any increased risk. It's that combination that makes these stocks great buys. * 7 Strong Buy Stocks Top Investors Are Buying Now Today, I am watching three under-the-radar cannabis stocks as potential investments. They aren't widely known, but I am confident that you will hear about them just as much as -- if not more than -- the likes of Canopy Growth and Tilray in the years ahead. Curaleaf (CURLF)Curaleaf (OTCMKTS:CURLF) is a leading U.S. cannabis company that most investors have overlooked. It operates 39 dispensaries, 12 cultivation facilities, and 10 processing sites throughout 12 states.This $3.4 billion company is a true growth story. Revenue in 2017 totaled $19.3 million, and management estimates that sales should reach $400 million this year. That's a 20X increase in just two years.Curaleaf is starting to gain attention on the Street after hitting a three-month high this week. But even at these levels, the stock is a steal based on its long-term outlook. Charlotte's Web (CWBHF)Charlotte's Web (OTCMKTS:CWBHF) is a $1.4 billion company and is already a leader in its industry, yet it remains unknown by most of Wall Street. But not if you've been reading my articles. Charlotte's Web is my pick in InvestorPlace's Best Stocks for 2019 contest, and it's already up nearly 30% this year.Charlotte's Web started garnering more attention after the Farm Bill was passed in late December. The legislation legalized hemp in the United States for the first time in more than 80 years. As the leader in market share for hemp-cannabidiol (CBD) products, this company is a surefire way to play the soon-to-be-booming hemp industry.There is huge growth potential here. One prediction has the U.S. hemp market growing from $800 million last year to $22 billion by 202. That's more than 20X growth in two years. * 7 Healthy Dividend Stocks to Buy for Extra Stability Do you see a trend emerging with these first two under-the-radar stocks? The Supreme Cannabis Company (SPRWF)Supreme Cannabis (OTCMKTS:SPRWF) is the smallest of the three, with a market cap of just $395 million. But that doesn't mean its potential is any less.This Canadian company produces medical marijuana, and it recently uplisted from the Toronto Venture Exchange to the Toronto Stock Exchange (TSX). The move is equivalent to uplisting from the OTC markets in the U.S. to the New York Stock Exchange.Companies on the TSX must meet more stringent requirements, but they also have a lot more visibility. It's a big deal that opens the door to more money flowing in.Earlier this week, SPRW reported quarterly earnings of $7.72 million, up from $1.8 million in the same quarter last year… nearly 330% year-over-year growth.That impressive figure combined with the move to the TSX should start to get this stock noticed. From there, the sky is the limit.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Monthly Dividend Stocks to Buy to Pay the Bills * 9 High-Growth Stocks to Buy Now for Monster Returns * 7 Healthy Dividend Stocks to Buy for Extra Stability Compare Brokers The post 3 Under-the-Radar Cannabis Stocks to Buy appeared first on InvestorPlace.